Search Results - "Dranoff, Jonathan"

Coffee as chemoprotectant in fatty liver disease: caffeine-dependent and caffeine-independent effects by Dranoff, Jonathan A

“…Coffee consumption is associated with a variety of positive health outcomes in patients with chronic liver disease, including decreased liver-related…”
Get more information

Coffee, adenosine, and the liver by Dranoff, Jonathan A.

“…A variety of observational studies have demonstrated that coffee, likely acting through caffeine, improves health outcomes in patients with chronic liver…”
Get full text

Portal fibroblasts: Underappreciated mediators of biliary fibrosis by Dranoff, Jonathan A., Wells, Rebecca G.

“…Portal fibroblasts are an important yet often overlooked nonparenchymal cell population in the liver. They are distinct from hepatic stellate cells, yet like…”
Get full text

Extracellular vesicles carry microRNA‐195 to intrahepatic cholangiocarcinoma and improve survival in a rat model by Li, Ling, Piontek, Klaus, Ishida, Masaharu, Fausther, Michel, Dranoff, Jonathan A., Fu, Rongdang, Mezey, Esteban, Gould, Stephen J., Fordjour, Francis K., Meltzer, Stephen J., Sirica, Alphonse E., Selaru, Florin M.

“…The cancer microenvironment plays a central role in cancer development, growth, and homeostasis. This paradigm suggests that cancer fibroblasts support…”
Get full text

Advances in cholangiocyte immunobiology by Syal, Gaurav, Fausther, Michel, Dranoff, Jonathan A

“…Cholangiocytes, or bile duct epithelia, were once thought to be the simple lining of the conduit system comprising the intra- and extrahepatic bile ducts…”
Get more information

Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014 by Torok, Natalie J., Dranoff, Jonathan A., Schuppan, Detlef, Friedman, Scott L.

“…There is an urgent need to develop antifibrotic therapies for chronic liver disease, and clarify which endpoints in antifibrotic trials will be acceptable to…”
Get full text

Establishment and characterization of rat portal myofibroblast cell lines by Fausther, Michel, Goree, Jessica R, Lavoie, Élise G, Graham, Alicia L, Sévigny, Jean, Dranoff, Jonathan A

“…The major sources of scar-forming myofibroblasts during liver fibrosis are activated hepatic stellate cells (HSC) and portal fibroblasts (PF). In contrast to…”
Get full text

Obesity, but not glycemic control, predicts liver steatosis in children with type 1 diabetes by Tas, Emir, Bai, Shasha, Mak, Daniel, Diaz, Eva C., Dranoff, Jonathan A.

“…Nonalcoholic fatty liver disease (NAFLD), the most common liver disease in children, is strongly associated with obesity and insulin resistance. Although type…”
Get full text

Effects of short‐term supervised exercise training on liver fat in adolescents with obesity: a randomized controlled trial by Tas, Emir, Landes, Reid D., Diaz, Eva C., Bai, Shasha, Ou, Xiawei, Buchmann, Robert, Na, Xiaoxu, Muzumdar, Radhika, Børsheim, Elisabet, Dranoff, Jonathan A.

“…Objective The objective of this study was to quantify the effects of a 4‐week, supervised, high‐intensity interval training (HIIT) on intrahepatic triglyceride…”
Get full text

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants by Fausther, Michel, G Lavoie, Elise, Dranoff, Jonathan A

“…Liver myofibroblasts are specialized effector cells that drive hepatic fibrosis, a hallmark process of chronic liver diseases, leading to progressive scar…”
Get full text

Macrophage Heterogeneity in Liver Injury: You Are Now Leaving Kupffertown by Dranoff, Jonathan A

Get full text

Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis by Dranoff, Jonathan A.

“…Coffee is acknowledged as the most widely used drug worldwide. Coffee is also a foodstuff, so its use is often used to satisfy dietary urges. When used as a…”
Get full text

Proteomics Indicates Lactate Dehydrogenase Is Prognostic in Acetaminophen-Induced Acute Liver Failure Patients and Reveals Altered Signaling Pathways by Vazquez, Joel H, Kennon-McGill, Stefanie, Byrum, Stephanie D, Mackintosh, Samuel G, Jaeschke, Hartmut, Williams, D Keith, Lee, William M, Dranoff, Jonathan A, McGill, Mitchell R

“…Abstract Better biomarkers to predict death early in acute liver failure (ALF) are needed. To that end, we obtained early (study day 1) and later (day 3) serum…”
Get full text

Transforming growth factor‐β and substrate stiffness regulate portal fibroblast activation in culture by Li, Zhaodong, Dranoff, Jonathan A., Chan, Erick P., Uemura, Masayuki, Sévigny, Jean, Wells, Rebecca G.

“…Myofibroblasts derived from portal fibroblasts are important fibrogenic cells in the early stages of biliary fibrosis. In contrast to hepatic stellate cells,…”
Get full text

Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline by Patel, Keyur, Asrani, Sumeet K, Fiel, Maria Isabel, Levine, Deborah, Leung, Daniel H, Duarte-Rojo, Andres, Dranoff, Jonathan A, Nayfeh, Tarek, Hasan, Bashar, Taddei, Tamar H, Alsawaf, Yahya, Saadi, Samer, Majzoub, Abdul Mounaem, Manolopoulos, Apostolos, Alzuabi, Muayad, Ding, Jingyi, Sofiyeva, Nigar, Murad, Mohammad H, Alsawas, Mouaz, Rockey, Don C, Sterling, Richard K

“…Blood-based biomarkers have been proposed as an alternative to liver biopsy for noninvasive liver disease assessment in chronic liver disease. Our aims for…”
Get full text

AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis by Sterling, Richard K, Duarte-Rojo, Andres, Patel, Keyur, Asrani, Sumeet K, Alsawas, Mouaz, Dranoff, Jonathan A, Fiel, Maria Isabel, Murad, M Hassan, Leung, Daniel H, Levine, Deborah, Taddei, Tamar H, Taouli, Bachir, Rockey, Don C

Get full text

AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis by Sterling, Richard K, Patel, Keyur, Duarte-Rojo, Andres, Asrani, Sumeet K, Alsawas, Mouaz, Dranoff, Jonathan A, Fiel, Maria Isabel, Murad, M Hassan, Leung, Daniel H, Levine, Deborah, Taddei, Tamar H, Taouli, Bachir, Rockey, Don C

Get full text

AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension by Sterling, Richard K, Asrani, Sumeet K, Levine, Deborah, Duarte-Rojo, Andres, Patel, Keyur, Fiel, Maria Isabel, Leung, Daniel H, Taouli, Bachir, Alsawas, Mouaz, Murad, M Hassan, Dranoff, Jonathan A, Taddei, Tamar H, Rockey, Don C

Get full text

Integrins, myofibroblasts, and organ fibrosis by Fausther, Michel, Dranoff, Jonathan A.

“…Myofibroblasts are the major source of extracellular matrix components that accumulate during tissue fibrosis, and hepatic stellate cells (HSCs) are believed…”
Get full text

Beyond scar formation: Portal myofibroblast‐mediated angiogenesis in the fibrotic liver by Fausther, Michel, Dranoff, Jonathan A.

Get full text